Literature DB >> 14997962

The effects of sildenafil on the cardiovascular response in men with spinal cord injury at or above the sixth thoracic level.

Karen D Ethans1, Alan R Casey, Orpha I Schryvers, Brian J MacNeil.   

Abstract

BACKGROUND: Sildenafil is efficacious for erectile dysfunction in men with spinal cord injury (SCI), but can induce hypotension in neurologically intact people. Those with SCI at or above the sixth thoracic level (T6) often have pre-existing hypotension, yet the cardiovascular response to sildenafil has not been studied in this group.
OBJECTIVE: To evaluate the effect of sildenafil on the cardiovascular response in men with complete SCI at or above T6.
METHODS: This was a randomized, double-blind, placebo-controlled, cross-over study. Twenty-three SCI participants were each randomly given placebo; sildenafil, 50 mg; and sildenafil, 100 mg; separated by at least 1 week. The following were measured before administration, and hourly for 4 hours afterward: (a) blood pressure (BP) and heart rate (HR), both supine and sitting; and (b) perceived dizziness on a visual analog scale upon sitting.
RESULTS: Analysis was done using a 4-way repeated-measures analysis of variance. No significant changes occurred with placebo. Sildenafil caused the following changes. Systolic BP changed little in thoracic spinal cord-injured (TSCI) participants, but decreased significantly (P < 0.005) in cervical spinal cord-injured (CSCI) participants. Diastolic BP decreased in all participants (P < 0.005). HR increased in the TSCI participants for 1 hour (P < 0.05), but was not altered in the CSCI participants. Dizziness increased in the TSCI participants after administration of 100 mg (P < 0.05) and in the CSCI participants after administration of 50 mg (P < 0.05). There were no adverse events or outcomes.
CONCLUSION: Sildenafil induces significant hypotension in people with cervical-level injuries--more so than in thoracic-level injuries--and can cause dizziness in both populations. It should be prescribed with caution and informed consent from the patient.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14997962     DOI: 10.1080/10790268.2003.11753687

Source DB:  PubMed          Journal:  J Spinal Cord Med        ISSN: 1079-0268            Impact factor:   1.985


  7 in total

Review 1.  Erectile dysfunction.

Authors:  Mohit Khera; Irwin Goldstein
Journal:  BMJ Clin Evid       Date:  2011-06-29

Review 2.  Treatments for erectile dysfunction in spinal cord patients: alternatives to phosphodiesterase type 5 inhibitors? A review study.

Authors:  G Lombardi; S Musco; J J Wyndaele; G Del Popolo
Journal:  Spinal Cord       Date:  2015-07-21       Impact factor: 2.772

Review 3.  Recommendations for discussing sexuality after spinal cord injury/dysfunction in children, adolescents, and adults.

Authors:  Marcalee Sipski Alexander; Craig J Alexander
Journal:  J Spinal Cord Med       Date:  2007       Impact factor: 1.985

4.  A placebo-controlled, multicenter, randomized, double-blind, flexible-dose, two-way crossover study to evaluate the efficacy and safety of sildenafil in men with traumatic spinal cord injury and erectile dysfunction.

Authors:  Sureyya Ergin; Berrin Gunduz; Hatice Ugurlu; Koncuy Sivrioglu; Sema Oncel; Haydar Gok; Belgin Erhan; Funda Levendoglu; Ozlem Senocak
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

Review 5.  Treatment of erectile dysfunction following spinal cord injury.

Authors:  Todd A Linsenmeyer
Journal:  Curr Urol Rep       Date:  2009-11       Impact factor: 3.092

Review 6.  The treatment of erectile dysfunction in patients with neurogenic disease.

Authors:  Anand N Shridharani; William O Brant
Journal:  Transl Androl Urol       Date:  2016-02

7.  A randomized double-blind, placebo-controlled, cross-over trial assessing the effect of tadalafil (Cialis) on the cardiovascular response in men with complete spinal cord injury above the sixth thoracic level: A Pilot Study.

Authors:  Karen D Ethans; Alan Casey; Mohamed Tarhoni; Mayur Nankar; Stella Entcheva
Journal:  Spinal Cord Ser Cases       Date:  2018-11-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.